NRX Pharmaceuticals (NRXP) Accumulated Expenses (2017 - 2026)

NRX Pharmaceuticals (NRXP) has reported Accumulated Expenses for 8 consecutive years, with $394000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses fell 96.0% year-over-year to $394000.0; the TTM figure through Mar 2026 stood at $394000.0 (down 96.0% YoY), while the FY2025 annual figure was $11.3 million, up 11.71% from the prior year.
• Accumulated Expenses retreated to $394000.0 in Q1 2026 per NRXP's latest filing, from $11.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $11.3 million in Q4 2025 and bottomed at $20000.0 in Q1 2022.
• Historically, Accumulated Expenses has averaged $4.7 million across 5 years, with a median of $5.1 million in 2023.
• Annual changes were most pronounced in 2023 — Accumulated Expenses soared 25170.0% — and 2026, when it sank 96.0%.
• NRX Pharmaceuticals' Accumulated Expenses stood at $923000.0 in 2022, then slipped by 9.53% to $835000.0 in 2023, then soared by 1115.45% to $10.1 million in 2024, then increased by 11.71% to $11.3 million in 2025, then slumped by 96.52% to $394000.0 in 2026.
• Business Quant data shows NRXP's Accumulated Expenses at $394000.0 in Q1 2026, $11.3 million in Q4 2025, and $420000.0 in Q3 2025.